"Bridging" and mechanical heart valves: Perils, promises, and predictions

Circulation

Volumn 113, Issue 4, 2006, Pages 470-472

  Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulants; Editorials; Stroke; Thrombosis; Valves

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; AORTA VALVE REPLACEMENT; BLEEDING; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EDITORIAL; HEART TAMPONADE; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MUSCLE HEMATOMA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SAINT JUDE HEART VALVE PROSTHESIS; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; NOTE; POSTOPERATIVE COMPLICATION; VALVULAR HEART DISEASE;

ANTICOAGULANTS; CEREBROVASCULAR ACCIDENT; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMANS; POSTOPERATIVE COMPLICATIONS; THROMBOSIS;

EID: 33644870400     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.598268     Document Type: Editorial

References (12)

1. Ageno W, Turpie AG. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol. 1999;84:905-908.
2. Fanikos J, Stapinski C, Koo S, Kucher N, Tsilimingras K, Goldhaber SZ. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol. 2004;94:532-535.
3. Amorosi SL, Tsilimingras K, Thompson D, Fanikos J, Weinstein MC, Goldhaber SZ. Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol. 2004;93:509-511.
4. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest. 2004;125:1642-1650.
5. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319-1326.
6. Hering D, Piper C, Bergemann R, Hillenbach C, Dahm M, Huth C, Horstkotte D. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest. 2005;127:53-59.
7. Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol. 2004;93:247-250.
8. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation. 2006;113:564-569.
9. Seshadri N, Goldhaber SZ, Elkayam U, Grimm RA, Groce JB III, Heit JA, Spinler SA, Turpie AG, Bosker G, Klein AL. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. Am Heart J. 2005;150:27-34.
10. Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Low molecular weight heparin after mechanical heart valve replacement. Circulation. 2000;101:1083-1086.
11. Grasso-Correnti N, Goldszer RC, Goldhaber SZ. The critical pathways of an anticoagulation service. Crit Pathways Cardiol. 2003;2:41-45.
12. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127:1515-1522.